Pannysylvania Magazine

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Chronic Obstructive Pulmonary Disease Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.

• Chronic Obstructive Pulmonary Disease companies working in the treatment market are AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment

• Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.

• In May 2026, Results from a randomized clinical study of EP395, an investigational anti-inflammatory macrolide, demonstrated promising anti-inflammatory effects along with a favorable safety profile in patients with stable COPD. The findings underscore ongoing efforts to develop innovative non-biologic treatment strategies for the management of chronic obstructive pulmonary disease.

• In April 2026, AstraZeneca announced further positive results from the Phase III MIRANDA trial, showing that tozorakimab achieved statistically significant reductions in COPD exacerbations among patients treated with standard inhaled therapies. These findings further reinforce the therapy’s promising late-stage clinical potential.

• In March 2026, AstraZeneca’s tozorakimab successfully met the primary endpoint in both the Phase III OBERON and TITANIA studies, demonstrating a significant reduction in moderate-to-severe COPD exacerbations. The IL-33-targeted monoclonal antibody showed efficacy across a diverse patient population, including both current and former smokers.

• In January 2026, Findings from the Phase III PACE trial assessing bisoprolol for the prevention of adverse cardiovascular events in patients with COPD were published, providing important insights into the management of cardiovascular comorbidities within the COPD population.

• In April 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for asthma and chronic obstructive pulmonary disease (COPD), has received encouraging feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), specifically the Division of Pulmonology, Allergy, and Critical Care within the Office of Immunology and Inflammation.

• In March 2025, SMSbiotech achieved a major milestone in advancing its regenerative medicine platform, receiving approval to initiate a Phase I clinical trial in Australia (registration number: ANZCTR12624001140549p). The trial aims to assess the safety and tolerability of the company’s novel Small Mobile stem (SMS) cell therapy for treating Chronic Obstructive Pulmonary Disease (COPD).

• In January 2025, Aer Therapeutics (“Aer”), a biopharmaceutical company focused on developing innovative inhaled therapies for mucus-related lung diseases, announced that the first patient has been dosed in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (previously known as AER-01) for Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes breathing difficulties due to airflow obstruction. It encompasses conditions such as chronic bronchitis and emphysema, primarily resulting from long-term exposure to irritants like cigarette smoke, air pollution, and occupational dust. Symptoms include persistent cough, mucus production, wheezing, and shortness of breath, especially during physical activity. COPD is characterized by its chronic nature, often leading to worsening lung function over time. While there is no cure, management options include medications, pulmonary rehabilitation, and lifestyle changes, such as smoking cessation, to improve quality of life and reduce symptoms.

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:

• Benralizumab: AstraZeneca

• Dupilumab: Sanofi

• Tezepelumab: Amgen

• SNG001: Synairgen

• GSK3923868: GlaxoSmithKline

• Ensifentrine: Verona Pharma

• SAR440340: Regeneron Pharma

• CHF 6001: Chiesi Farmaceutici S.p.A

• QBW-251: Novartis

• Tezepelumab: AstraZeneca

• Anti-ST2: Genentech

• PBF-680: Palobiofarma

• PUR1800: Pulamtrix

Chronic Obstructive Pulmonary Disease Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Intramuscular

Chronic Obstructive Pulmonary Disease Molecule Type

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

• Chronic Obstructive Pulmonary Disease Assessment by Product Type

• Chronic Obstructive Pulmonary Disease By Stage and Product Type

• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration

• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration

• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type

• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight’s Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:

Key companies developing therapies for Chronic Obstructive Pulmonary Disease are – Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:

The Chronic Obstructive Pulmonary Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.

• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers

• Rising global prevalence of COPD, driven by smoking, air pollution, occupational exposures, and aging populations, is increasing demand for innovative therapies.

• Significant unmet medical need for disease-modifying treatments beyond symptomatic management is fueling pipeline development.

• Growing awareness and improved diagnosis rates are expanding the identified patient population eligible for treatment.

• Advances in biologics and targeted therapies, particularly for eosinophilic and inflammatory COPD phenotypes, are driving innovation.

• Increasing research into regenerative medicine and novel anti-inflammatory mechanisms is broadening therapeutic opportunities.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers

• Complex and heterogeneous disease biology makes it challenging to develop universally effective therapies.

• High clinical trial costs and lengthy study durations are required to demonstrate meaningful improvements in lung function and exacerbation rates.

• Difficulty in identifying reliable biomarkers and clinical endpoints can complicate drug development and regulatory approval.

• Stringent regulatory requirements for demonstrating long-term efficacy and safety may delay product approvals.

• High failure rates in late-stage clinical trials due to limited efficacy in diverse patient populations remain a key concern.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight

• Coverage: Global

• Key Chronic Obstructive Pulmonary Disease Companies: AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others

• Key Chronic Obstructive Pulmonary Disease Therapies: Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others

• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Obstructive Pulmonary Disease Report Introduction

2. Chronic Obstructive Pulmonary Disease Executive Summary

3. Chronic Obstructive Pulmonary Disease Overview

4. Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Obstructive Pulmonary Disease Pipeline Therapeutics

6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)

7. Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)

8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)

9. Chronic Obstructive Pulmonary Disease Preclinical Stage Products

10. Chronic Obstructive Pulmonary Disease Therapeutics Assessment

11. Chronic Obstructive Pulmonary Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Obstructive Pulmonary Disease Key Companies

14. Chronic Obstructive Pulmonary Disease Key Products

15. Chronic Obstructive Pulmonary Disease Unmet Needs

16 . Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

17. Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion

18. Chronic Obstructive Pulmonary Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/